Biography
Dr. Harvey Pass is a pioneer in mesothelioma biomarker research at NYU Langone. His groundbreaking work on soluble mesothelin-related peptides (SMRP) as a blood-based biomarker for mesothelioma, published in the New England Journal of Medicine, has been instrumental in advancing early detection methods for the disease. Dr. Pass trained at Johns Hopkins and the National Cancer Institute (NIH) and has published over 300 research papers. He combines mesothelioma surgery with a world-class research program.
Education & Training
- Medical Degree — Johns Hopkins University School of Medicine (Medicine)
- Residency — Duke University Medical Center (General Surgery)
- Fellowship — National Cancer Institute (NIH) (Thoracic Surgery/Surgical Oncology)
Specialties & Procedures
Clinical Specialties
- Thoracic Surgery
- Surgical Oncology
- Mesothelioma Biomarkers
Surgical Procedures
Board Certifications
- American Board of Thoracic Surgery
- American Board of Surgery
Research Focus
Mesothelioma biomarkers for early detection, soluble mesothelin-related peptides (SMRP), and blood-based diagnostic tests for mesothelioma.
Notable Publications
- Soluble mesothelin-related peptides as a biomarker for mesothelioma. New England Journal of Medicine, 2005.
Treatment Center
Dr. Harvey Pass practices at NYU Langone Perlmutter Cancer Center in New York, NY.
Legal Resources for Mesothelioma Patients
Patients diagnosed with mesothelioma after asbestos exposure may be eligible for compensation through asbestos trust funds and legal claims. Over $30 billion remains available in trust funds nationwide.
Frequently Asked Questions
What is Dr. Pass known for?
Dr. Pass is internationally recognized for his discovery of soluble mesothelin-related peptides (SMRP) as a blood-based biomarker for mesothelioma, published in the New England Journal of Medicine. He is also an experienced mesothelioma surgeon with over 300 publications.